New advances in myeloma treatment, the new mechanism of action drug Selinexor (ATG-010) three treatment options were selected in the latest edition of NCCN® multiple myeloma diagnosis and treatment guidelines

On December 15th Deki Pharmaceuticals Co., Ltd. ("Deki Pharmaceuticals") announced that the National Comprehensive Cancer Network (NCCN? In the latest edition of the Clinical Practice Guide for Multiple Myeloma (NCCN Guidelines? Three combinations of selinexor (ATG-010) for treating patients with recurring multiple myeloma (rrMM) have been added: SVd solutions based on BOSTON research support (selinexor, borontzomi, dexami) Pine), based on the SDd scheme supported by the STOMP study (selinexor-Daleitoyu monoanti-dexamethason) and spinexor-pomadamine-desamethasson), wherein SPd is an all-oral treatment.
this NCCN? The guide update only covers the update of the selinexor content, and it is worth noting that the SVd scheme has become a category 1 recommendation of the guide, which also indicates that the treatment option with selinexor as the skeleton will provide MM patients with new treatment options.
multiple myeloma is a malignant disease of abnormal proliferation of cloned plasma cells, which is the second most common malignant tumor in the blood system in many countries1.
rrMM is still incurable and prone to recurrence, and there is a lack of standard treatment options after recurrence.
more and more new drugs are being used in the clinic, how to choose the right treatment is also a clinical challenge.
NCCN guidelines will provide important guidance for the treatment of rrMM patients, and hematologists at home and abroad are very concerned about the update of the guidelines, and have given high praise to Selinexor's entry into the new NCCN guidelines.
"Recently, the NCCN guidelines for multiple myeloma have been updated to the fourth edition of 2021, and several options for selinexor have been included in the latest version of the recommended guidelines," said Professor Qiu Yugui of the Hospital of Hematology of the Chinese Academy of Medical Sciences.
, selinexor's weekly programmes (SVds) of co-boron tyzomi and dexamisong have been included in the recommendations of a class of programmes for patients with relapsed rrMM.
the efficacy and safety of SVd in patients with relapsed rrMM who have previously received 1-3-line treatment was published in LANCET this year, and the data are encouraging.
is conducting a joint Phase II clinical trial in China, where the effectiveness and safety of the program is similar to that of registered clinical trials in the United States, and no new safety events have occurred.
with our growing understanding of the selinexor joint solution and the growing experience in clinical applications, we believe that selinexor will give rrMM patients more hope of survival.
professor Fu Weijun, of Shanghai Long March Hospital, said: "On December 10th, NCCN's latest MM guidelines added treatment options, providing more options for the treatment of rrMM patients.
, we also saw a familiar drug, celinexor, which was recently presented at a major conference in the field of hematoma.
from previously published data, SVd treatment of patients with relapsed rrMM after 1-3 line treatment, total efficiency (ORR) of 76%, SPd treatment of multiple recurrence of rrMM patients, ORR close to 60%, the effect is significant.
addition, selinexor combined with the Dretoyu monoantitherapy treatment program can improve the overall efficacy.
study ad fittingly illustrates that celinexor, as a drug with a new mechanism of action, can be effectively combined with existing drugs to further improve efficacy and prolong patients' progression-free life.
I hope to see more clinical data in Chinese patients in the future, and to benefit more MM patients based on its outstanding efficacy as early as possible in the China recommendation guidelines.
Dr. Jianming Mei, Founder, Chairman and CEO of deji Pharmaceuticals, said, "Selinexor's recommendation guidelines for entering the NCCN are based on the remarkable efficacy of the product in treating recurring refractory multiple myeloma, the accessability and development potential of selective nuclear output inhibitors for tumor therapy, and the effectiveness and development potential of oral drugs based on this new mechanism to effectively match the clinical needs of patients."
It is an honor to see Selinexor recognized by professionals and professional associations, and we will continue to explore the clinical potential of this drug to maximize the benefits to patients in China, Asia Pacific and around the world."
NCCN guidelines are currently the best treatment guidelines for medical professionals around the world, and three different selinexor combinations have entered the guidelines to further validate the importance of selinexor in future treatment of multiple myeloma.
About Selinexor (ATG-010, XPOVIO) Selinexor (ATG-010, XPOVIO) is the first and only oral selective nuclear output inhibitor (SINE) compound of its kind, developed by Deki Pharmaceuticals in collaboration with Karopharm Therapeutics Inc.
July 2019, the U.S. Food and Drug Administration (FDA) approved selinexor combined with low-dose dexamisong for the treatment of patients with recurring multiple myeloma (rrMM).
June 2020, the FDA again approved selinexor as a single-drug oral therapy for the treatment of patients with recurring refractic, incurable large B-cell lymphoma (rrDLBCL).
is the first and only oral SINE compound approved by the FDA.
, Selinexor conducted a number of mid- and post-clinical trials for multiple solid tumor adaptations, including liposarcoma and endometrial cancer.
In November 2020, Deki Pharmaceutical Partner Karyopharm reported positive data from the Phase III SEAL study, a randomized, double-blind, placebo-controlled cross-study designed to compare the efficacy of oral monodripose selinexor with placebo in patients with liposarcoma, at the 2020 Annual Meeting of connective tissue oncology (CTOS 2020).
Karyopharm recently published the Phase III SIENDO study for the treatment of endometrial cancer patients, which has passed a planned medium-term ineffectiveness analysis.
, the Data Security Monitoring Board (DSMB) recommended that the SIENDO study proceed without any modifications as planned, and the top-line data for the SIENDO trial is expected to be released in the second half of 2021.
Deqi Pharmaceuticals is conducting a Phase II registered clinical study (code-named MARCH) on recurring multiple myeloma in China, as well as a phase II registered clinical study (code-named SEARCH) on recurring diffuseric large B-cell lymphoma.
at the same time, Deqi Pharmaceuticals initiated clinical studies (code-named TRUMP) for the treatment of external T-cell lymphoma, NK/T-cell lymphoma (code-named TOUCH) and KRAS mutated non-small cell lung cancer for Asia Pacific high-risk tumors.
About Deki Pharmaceuticals Deqi Pharmaceuticals, Inc. ("Deki Pharmaceuticals") is an Asia-Pacific clinical phase biopharmaceutical company focused on innovative anti-tumor drugs designed to provide cutting-edge, innovative anti-tumor therapies to patients in China, Asia Pacific and around the world.
Since its inception, Deqi Pharmaceuticals has established a rich product pipeline with 12 clinical and preclinically innovative drugs, obtained 10 clinical approvals, and conducted 10 cross-regional clinical trials in the Asia Pacific region.
Deqi people to "doctors without borders, innovation and sustainable" as the vision, and strive to solve the Asia-Pacific and even the world's patients unseeded clinical needs through the first of its kind / the best treatment of the same kind of research and marketization.
Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mace Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here